Drug
Karxt
Karxt: highest development phase Post-Market, developed by Bristol-Myers Squibb, Karuna Therapeutics. 12 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bristol-Myers Squibb, Karuna Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| KarXT NCT07681076 | Post-Market | Healthy Volunteers |
| KarXT NCT05511363 | Phase 3 | Psychosis Associated With Alzheimer's Disease |
| KarXT NCT06585787 | Phase 3 | Alzheimer Disease |
| KarXT NCT05980949 | Phase 3 | Psychosis Associated With Alzheimer's Disease |
| KarXT NCT07424404 | Phase 3 | Schizophrenia |
| KarXT NCT06126224 | Phase 3 | Psychosis Associated With Alzheimer's Disease |
| KarXT NCT06572449 | Phase 3 | Schizophrenia |
| KarXT NCT07285798 | Phase 3 | Irritability Associated With Autism Spectrum Disorder |
| KarXT NCT07284745 | Phase 3 | Irritability Associated With Autism Spectrum Disorder |
| KarXT NCT06951711 | Phase 3 | Bipolar Disorder Type I With Mania or Mania With Mixed Features |
| KarXT NCT07118215 | Phase 1 | Healthy Volunteers |
| KarXT NCT06605950 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Karxt on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.